Liquid Biopsy

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, spoke with Healio about presentations from the Chemotherapy Foundation Symposium exploring liquid biopsy in lung cancer.

In this video, Charu Aggarwal, MD, MPH, Leslye M. Heisler assistant professor for lung cancer excellence at the University of Pennsylvania Abramson Cancer Center, discusses the role of liquid biopsies for the management of non-small cell lung cancer.

The FDA has approved a new pan-tumor liquid biopsy test that can help guide treatment decisions for patients with solid tumors. It was the top story in hematology/oncology last week.

The FDA approved FoundationOne Liquid CDx, a comprehensive pan-tumor liquid biopsy test.

The past decade has ushered in major transformations in the prevention, diagnosis and treatment of melanoma.

The FDA today approved Guardant360 CDx, a liquid biopsy companion diagnostic that uses next-generation sequencing, to identify EGFR mutations in patients with metastatic non-small cell lung cancer.

The U.S. Preventive Services Task Force has issued a draft recommendation that lowers the age to begin lung cancer screening in individuals with a history of smoking. It was the top story in hematology/oncology last week.

Private and public coverage of liquid biopsy genomic testing for cancer increased significantly between 2015 and 2019, according to results of a retrospective study published in JNCCN — Journal of the National Comprehensive Cancer Network.

A liquid biopsy has shown promise for the early detection and staging of pancreatic ductal adenocarcinoma.

Although tissue biopsy is currently the standard of care for non-small cell lung cancer, liquid biopsy is a promising, minimally invasive technique for diagnosing and monitoring patients, with this technology quickly becoming a clinical reality.